Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 701 - 750 out of 12,713

Document Document Title
WO/2016/016447A1
A process for the preparation of a compound of formula (I) including all isomers, stereoisomers, enantiomers and diastereomers thereof (I), and salts thereof; the process comprising providing a mixture comprising a compound of formula (I...  
WO/2016/012781A1
The present invention provides a process for the preparation of gemcitabine-[phenyl(benzoxy-L-alaninyl)] phosphate of Formula I in high yield and purity.  
WO/2016/014927A2
Provided are crystalline forms of nicotinamide riboside, including a Form I of nicotinamide riboside chloride according to formula (I). Also disclosed are pharmaceutical compositions comprising the crystalline Form I of nicotinamide ribo...  
WO/2016/008461A1
The crystalline Form Z-1 of sofosbuvir, characterized by the following diffraction peaks: 8.0; 12.3; 17.1; 19.9 and 20.8 ±0,2° 2-theta with the use of CuKα radiation, and a method of its preparation.  
WO/2016/011360A1
The present invention provides methods and compositions for enhancing efficacy of anti-hormone treatment, or for preventing cancer relapse or progression following treatment. The invention also provides methods for re-sensitizing or sens...  
WO/2015/200216A1
Disclosed herein are methods of preparing a phosphoroamidate nucleotide anal which are useful in treating diseases and/'or conditions such as viral infections.  
WO/2015/198058A1
Prodrug This invention relates to a prodrug of the monophosphate nucleotide of the well-known oncology drug gemcitabine. Specifically, it relates to gemcitabine-[phenyl-benzoxy-L- alaninyl)]-phosphate when present as a single phosphate d...  
WO/2015/198059A1
This invention relates to pharmaceutical formulations of gemcitabine-[phenyl-benzoxy-L- alaninyl)]-phosphate, a monophosphate derivative of the well-known oncology drug gemcitabine. In particular, the invention relates to formulations wh...  
WO/2015/168461A3
Aspects of the present disclosure include compositions that make use of phosphorus and/or nucleobase protecting groups which find use in the synthesis of long polynucleotides. Phosphorus protecting groups are provided that help increase ...  
WO/2015/027137A8
Provided herein are compounds of Formula I, Formula II, and Formula X, which are useful for the treatment of infectious diseases. Also provided herein are processes for preparing 1-[5-0-[4,6-Dideoxy-6-oxo-6-[[[(3S)-hexahydro-2-oxo-1H-aze...  
WO/2015/188782A1
The present invention relates to a method for preparing sofosbuvir. In particular, provided in the present invention is a more stereoselective preparation method. The preparation method has the advantages of a richer required isomer prep...  
WO/2015/081133A3
Provided herein are compounds, compositions and methods for the treatment of liver cancer such as hepatocellular carcinoma, cholangiocarcinoma, or biliary tract cancer. In certain embodiments, compounds and compositions of nucleoside der...  
WO/2015/185565A1
A compound of formula (I) or a pharmaceutically acceptable salt and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of sai...  
WO/2015/186068A1
Provided herein are crystalline beta-D-nicotinamide riboside chloride compositions and methods of preparation and use thereof. Also provided are related pharmaceutical compositions and methods of use thereof. The crystalline beta-D-nicot...  
WO/2015/186114A1
Provided herein are stereoisomerically pure ester and carbonate analogues of nicotinamide riboside and nicotinamide riboside hydride, and pharmaceutical compositions and uses thereof. The stereoisomerically pure ester and carbonate analo...  
WO/2015/181624A2
Provided herein are compounds, compositions, and methods for the treatment of cancer, including leukemia. In one embodiment, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in...  
WO/2015/181201A1
A composition comprising a) a compound of Formula (I), where R1, R2, and R3 are, each one and independently, hydrogen or a protector group, wherein said protector group may consist of an alkyl group, a cycloalkyl group, a heterocyclic cy...  
WO/2015/176542A1
Disclosed are an adenosine derivative as represented by formula I, and synthesis preparation process and use thereof in treating hyperlipidemia, fatty liver and atherosclerosis. Particularly, disclosed is a novel compound N6-(1-(4-methox...  
WO/2015/179284A1
This disclosure is related to a method for determining the identity of a nucleotide residue of a single- stranded DNA or RNA, or sequencing DNA or RNA, in a solution using an ion-sensing field effect transistor and reversible nucleotide ...  
WO/2015/178265A1
It was discovered that interposing a suitable aromatic amidation linker in making a prodrug to serve as a γ-glutamylation drug provides stability even in a close to physiological environment, recognition by GGT, and very rapid release o...  
WO/2015/051169A3
The present disclosure provides alternative sugar moieties and polynucleotides comprising such sugar moieties, and methods of use thereof.  
WO/2015/168172A1
The present invention provides oligomeric compounds comprising at least one neutral methoxypropyl phosphonate modified internucleoside linkage. Such oligomeric compounds have one or more improved properties such as selectivity, potency, ...  
WO/2015/120237A3
The application discloses nucleoside derivatives of Formula I as inhibitors of Influenza RNA replication. In particular, the application discloses the use of purine and pyrimidine nucleoside derivatives of Formula I as inhibitors of Infl...  
WO/2015/089511A3
The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using them.  
WO/2015/167620A1
The present invention generally relates to compounds that include one or more thermally labile protecting groups, compositions including the compounds, methods of making the compounds and compositions and methods of using the compounds a...  
WO/2015/167616A1
Methods and Compositions involving the administration of guanosine, identified as Toll like receptor (TLR) 2 and 4 agonists, that will be useful for enhancing the potency of vaccine and cancer immunotherapies are disclosed. Method of pre...  
WO/2015/168461A2
Aspects of the present disclosure include compositions that make use of phosphorus and/or nucleobase protecting groups which find use in the synthesis of long polynucleotides. Phosphorus protecting groups are provided that help increase ...  
WO/2015/164812A1
The present invention is directed to compounds, compositions and methods for treating or preventing Flaviviridae family of viruses (including HCV, Yellow fever, Dengue, Chikungunya and West Nile virus), RSV and influenza infection and ca...  
WO/2015/162130A1
The present disclosure provides novel compounds containing a base- modified nucleoside of formula and methods for detecting the presence of guanine in a nucleic acid and for isolating O6-alkyl guanine comprising nucleic acid. The disclos...  
WO/2015/164770A1
Colorimetry is used to detect amplification reaction products. A sample is contacted with a reaction mix under conditions such that an amplification reaction occurs and produces an amplification reaction product if the sample contains a ...  
WO/2015/164573A1
Provided are novel compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are inhibitors of CD73 and are useful in the treatment of cancer.  
WO/2015/158913A1
The present invention relates to novel phosphate-modified nucleosides, such as phosphoramidate nucleosides. The invention also relates to the use of these novel phosphate-modified nucleosides to treat or prevent viral infections and prol...  
WO/2015/161137A1
Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be admi...  
WO/2015/155739A1
The present application discloses a stereoselective process for the preparation of β-C-arylglucosides that does not require the use of conventional carbohydrate protecting groups.  
WO/2015/153496A1
Disclosed are modified thymine bases that provide enhanced base-pairing affinity for adenine or 2,6-diaminopurine bases in polynucleotide hybridization complexes. Also disclosed are polynucleotide oligomers, polynucleotide hybridization ...  
WO/2015/148746A1
The present invention is directed to 4'-substituted nucleoside derivatives of Formula I (Formula I), and their use in the inhibition of HIV reverse transcriptase, the prophylaxis of infection by HIV, the treatment of infection by HIV, an...  
WO/2015/144282A1
The invention relates to an inorganic-organic hybrid compound as an ion compound, composed of an inorganic cation and an organic anion active substance and optionally, an organic anion fluorescent dye.  
WO/2015/148402A1
This disclosure provides systems and methods for attaching nano pore-detectable tags to nucleotides. The disclosure also provides methods for sequencing nucleic acids using the disdosed tagged nudeotides. Provided herein are nudeotides w...  
WO/2015/148522A1
This invention is about the compositions and methods for assessing and treating vascular endothelial dysfunction. Various aspects provide a method for treatment of vascular endothelial dysfunction, comprising administering a composition ...  
WO/2015/143712A1
Provided is 4'-substituted nucleoside derivatives of Formula I and their use in the inhibition of HIV reverse transcriptase, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and dela...  
WO/2015/139602A1
Disclosed are 2'-substituted-2,2'-dehydrated uridine or 2'-substituted-2,2'-dehydrated cytidine compounds as represented by the following general formula I and preparation method thereof. The present invention also relates to a method of...  
WO/2015/137121A1
Provided is a means for producing a non-natural nucleoside analog in which position 5 is a hydroxyl group and which is for synthesizing a triazole linking-type non-natural nucleotide having a structure bonded via organic groups containin...  
WO/2015/133491A1
Provided are: an oligonucleotide having, at 5'-terminal thereof, a nucleotide or nucleoside residue represented by formula (I) {wherein X1 represents an oxygen atom or the like; R1 represents formula (IIA) (wherein R5A represents a halog...  
WO/2015/133411A1
The purpose of the present invention is to search for: a free acid crystal of 3',5'-cyclic diguanylic acid, which does not contain a salt with a metal such as cobalt and magnesium; and a method for producing the crystal in a simple manne...  
WO/2015/134780A1
Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be admi...  
WO/2015/134334A1
Gemcitabine analogs, including monophosphorylated analogs, are described herein and are suitable for use in pharmaceutical compositions, kits and treatment methods. The treatment methods include treatment of viral infections, including, ...  
WO/2015/132577A1
The invention relates to compounds for use in the modification of compounds comprising nucleic acid sequences (such as oligonucleotides or the like), to modified oligonucleotides, to the delivery of modified oligonucleotides to cells and...  
WO/2015/125845A1
 Provided are: a oligonucleotide having at least one bond represented by formula (I): (in the formula, Q is S or O, X1 does not exist, or is a substituted or unsubstituted alkylene in which O may be interposed, X2 is a substituted or u...  
WO/2015/125783A1
Disclosed are a crosslinked nucleoside and nucleotide. The nucleoside has a 2',4'-crosslinked structure, and is represented by formula (I). An oligonucleotide containing a 2',4'-crosslinked artificial nucleotide according to the present ...  
WO/2015/126995A1
The present disclosure encompasses solid state forms of Sofosbuvir and pharmaceutical compositions thereof.  

Matches 701 - 750 out of 12,713